Developer docs
API playgroundTry for free, no card

Search company profiles

Azafaros

Full company profile

uuid0000cgn

Namestring
Azafaros
Legal namestring
Azafaros B.V.
Websiteurl
azafaros.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Azafaros B.V. is a clinical-stage biopharmaceutical company founded in 2018 in Leiden, the Netherlands, developing orally administered, brain-penetrant therapies for severe rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (Tay-Sachs and Sandhoff diseases) and Niemann-Pick type C (NPC) disease. The company's scientific foundation is an exclusive worldwide license from Leiden University and Amsterdam UMC to a library of patented azasugar compounds, from which its lead clinical candidate nizubaglustat (AZ-3102) was advanced. Nizubaglustat is described as a small molecule with a unique dual mode of action that inhibits both non-lysosomal glucosylceramidase (NLGase/GbA2) and glucosylceramide synthase (GCS), modulating glycosphingolipid metabolism to reduce toxic substrate accumulation in the central nervous system.

The company is operating a single-asset late-stage clinical strategy: it initiated a Phase 1 study in healthy volunteers in April 2021, fully enrolled a 13-patient Phase 2 RAINBOW study in GM2 gangliosidosis and NPC by December 2023, reported positive topline data in July 2024, and began two global Phase 3 NAVIGATE registrational studies in July 2025, with topline Phase 3 data expected in 2028. Azafaros has accumulated a broad set of regulatory designations across jurisdictions, including FDA Orphan Drug, Rare Pediatric Disease, and Fast Track Designations, EMA Orphan Medicinal Product Designations, and a UK MHRA Innovation Passport, which together create material exclusivity incentives and accelerate review pathways upon filing.

Azafaros is currently pre-revenue and has not commercialized any product. Its intended business model is standard orphan-disease pharmaceutical commercialization: prescription drug sales to a small, highly specialized prescriber base of academic medical centers and rare disease clinics, with pricing expected to follow orphan drug economics upon regulatory approval. The company is backed by a syndicate of European healthcare investors led by Forbion (founding investor through Series A and co-lead of Series B) and Jeito Capital (lead of the EUR 132 million Series B in May 2025), with additional participation from Seroba, Pictet Group, BioGeneration Ventures (founding), BioMedPartners, Asahi Kasei Pharma Ventures, and Schroders Capital. Operations are based in Leiden and Naarden (Netherlands) with a Swiss R&D subsidiary, Azafaros AG, in Basel.

Short descriptiontext

Azafaros is a clinical-stage Dutch biotech developing nizubaglustat, an oral brain-penetrant azasugar with a dual NLGase/GCS mechanism, for rare lysosomal storage disorders including GM1/GM2 gangliosidoses and Niemann-Pick type C disease, currently in two global Phase 3 registrational studies.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNaarden, Netherlands
HQ citystring
Naarden
HQ countrystring
Netherlands
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
rare disease therapeutics, lysosomal storage disorders, orphan drug development, clinical-stage biotechnology, small molecule pharmaceuticals
Industry1 code
PRIMARYHLAIAIAN
Rare Pediatric & Congenital Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code1 code
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Medicinal Chemicals & Botanical Products2833
Product category
Rare Disease Pharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Sales
TypeOne Time License
Description

Pre-revenue clinical-stage biotech company. Once nizubaglustat receives regulatory approval, revenue will be generated through prescription drug sales for rare lysosomal storage disorders. The company is preparing for drug marketing authorization filings and commercial launch targeting patients with GM1/GM2 gangliosidoses and Niemann-Pick type C disease.

azafaros.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Azafaros is a clinical-stage biotech company developing nizubaglustat (AZ-3102), an orally available, brain-penetrant azasugar small molecule with a unique dual mode of action inhibiting both NLGase and GCS enzymes. The drug is being advanced through Phase 3 registrational studies (NAVIGATE) for the treatment of rare lysosomal storage disorders including GM1 and GM2 gangliosidoses and Niemann-Pick type C disease.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 22% survival increase (26 additional days) in Sandhoff disease mouse model at doses as low as 0.2 mg/kg/day
+3 more records
Product overview1 text field

Azafaros is a clinical-stage biotech company with one lead product candidate, nizubaglustat (also referred to as AZ-3102). Nizubaglustat is an orally available, brain-penetrant small molecule azasugar with a unique dual mode of action that modulates glycosphingolipid metabolism. The company is advancing nizubaglustat through Phase 3 registrational studies (NAVIGATE) for the treatment of GM1 and GM2 gangliosidoses and Niemann-Pick type C disease. The company was founded in 2018 and holds an exclusive license from Leiden University and Amsterdam UMC to a library of novel compounds.

Product and service1 record
1Nizubaglustat (AZ-3102)
CategoryRare disease pharmaceutical / Orphan drug
Description

An orally available, brain-penetrant small molecule azasugar with a unique dual mode of action targeting both NLGase and GCS enzymes, being developed as a potential disease-modifying treatment for rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses and Niemann-Pick type C disease.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierResearch CollaboratorTypeStrategic or Co-development Partner
Description

Collaboration with Queen's University Department of Pediatrics led by Dr. Jagdeep Walia for preclinical efficacy studies of nizubaglustat in GM2 gangliosidosis (Sandhoff disease mouse model). Published in Journal of Inherited Metabolic Disease.

Strategic tierCore PartnershipTypeStrategic or Co-development Partner
Description

Collaborations with patient organizations including National Tay-Sachs & Allied Diseases Association (NTSAD), National Niemann-Pick Disease Foundation (NNPDF), CATS Foundation, and NPUK for optimizing clinical trial design and patient engagement initiatives.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biotech developing AAV gene therapies for GM1 and GM2 gangliosidoses, directly competing with Azafaros's nizubaglustat in the same lead indications using a different modality (gene therapy vs small molecule).

TypeBroad incumbent
Description

Established rare disease leader with multiple approved enzyme replacement and small molecule therapies for lysosomal storage disorders (Vimizim, Naglazyme, Aldurazyme), making it the closest large-cap comparable and likely strategic acquirer for Azafaros.

TypeBroad incumbent
Description

Commercial-stage rare disease company focused on metabolic and neurological disorders, where Azafaros's CEO Stefano Portolano previously served as Head of Europe; comparable commercial model targeting specialized rare disease treatment centers globally.

TypeBroad incumbent
Description

Owns the leading LSD franchise (Cerezyme, Fabrazyme, Myozyme, Aldurazyme) and miglustat (via legacy Actelion) for NPC, making it both a competitor in NPC and a likely strategic acquirer for any approved GM1/GM2 therapy.

TypeDirect peer
Description

Late-stage developer of Trappsol (hydroxypropyl beta cyclodextrin) for Niemann-Pick type C disease, directly competing with nizubaglustat in the NPC indication with a different mechanism of action.

TypeEmerging player
Description

Clinical-stage rare disease company with approved and pipeline assets in lysosomal and neurodegenerative disorders, with overlapping interest in NPC and other LSDs where nizubaglustat is being developed.

TypeBroad incumbent
Description

Large rare disease franchise (Soliris, Strensiq, Kanuma) with established commercial infrastructure in ultra-rare metabolic disorders and active BD presence in CNS and LSDs.

TypeEmerging player
Description

Clinical-stage gene therapy company with CNS-targeted AAV programs including GM1 gangliosidosis, representing an alternative modality competing for the same patient population as nizubaglustat.

TypeBroad incumbent
Description

Holds miglustat (Zavesca) as the only approved NPC therapy via the Actelion acquisition; the incumbent standard of care in the NPC indication where Azafaros is running a pivotal Phase 3.

TypeBroad incumbent
Description

Large rare disease franchise including Replagal, Elaprase, and Adynovate for LSDs; Azafaros COO previously led rare disease business development at Takeda, making it a logical strategic partner or acquirer.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance10 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Azafaros

Rare Disease Pharmaceuticalsazafaros.com

Azafaros is a clinical-stage Dutch biotech developing nizubaglustat, an oral brain-penetrant azasugar with a dual NLGase/GCS mechanism, for rare lysosomal storage disorders including GM1/GM2 gangliosidoses and Niemann-Pick type C disease, currently in two global Phase 3 registrational studies.

What Azafaros does

Azafaros B.V. is a clinical-stage biopharmaceutical company founded in 2018 in Leiden, the Netherlands, developing orally administered, brain-penetrant therapies for severe rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (Tay-Sachs and Sandhoff diseases) and Niemann-Pick type C (NPC) disease. The company's scientific foundation is an exclusive worldwide license from Leiden University and Amsterdam UMC to a library of patented azasugar compounds, from which its lead clinical candidate nizubaglustat (AZ-3102) was advanced. Nizubaglustat is described as a small molecule with a unique dual mode of action that inhibits both non-lysosomal glucosylceramidase (NLGase/GbA2) and glucosylceramide synthase (GCS), modulating glycosphingolipid metabolism to reduce toxic substrate accumulation in the central nervous system.

The company is operating a single-asset late-stage clinical strategy: it initiated a Phase 1 study in healthy volunteers in April 2021, fully enrolled a 13-patient Phase 2 RAINBOW study in GM2 gangliosidosis and NPC by December 2023, reported positive topline data in July 2024, and began two global Phase 3 NAVIGATE registrational studies in July 2025, with topline Phase 3 data expected in 2028. Azafaros has accumulated a broad set of regulatory designations across jurisdictions, including FDA Orphan Drug, Rare Pediatric Disease, and Fast Track Designations, EMA Orphan Medicinal Product Designations, and a UK MHRA Innovation Passport, which together create material exclusivity incentives and accelerate review pathways upon filing.

Azafaros is currently pre-revenue and has not commercialized any product. Its intended business model is standard orphan-disease pharmaceutical commercialization: prescription drug sales to a small, highly specialized prescriber base of academic medical centers and rare disease clinics, with pricing expected to follow orphan drug economics upon regulatory approval. The company is backed by a syndicate of European healthcare investors led by Forbion (founding investor through Series A and co-lead of Series B) and Jeito Capital (lead of the EUR 132 million Series B in May 2025), with additional participation from Seroba, Pictet Group, BioGeneration Ventures (founding), BioMedPartners, Asahi Kasei Pharma Ventures, and Schroders Capital. Operations are based in Leiden and Naarden (Netherlands) with a Swiss R&D subsidiary, Azafaros AG, in Basel.

Azafaros firmographics

Firmographics
Name
Azafaros
Legal name
Azafaros B.V.
Website
https://azafaros.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Short description
Azafaros is a clinical-stage Dutch biotech developing nizubaglustat, an oral brain-penetrant azasugar with a dual NLGase/GCS mechanism, for rare lysosomal storage disorders including GM1/GM2 gangliosidoses and Niemann-Pick type C disease, currently in two global Phase 3 registrational studies.
Ownership category
akta.pro rank

Azafaros industry classification

Industry
Product category
Rare Disease Pharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (3254)
SIC
Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAIAIAN
Rare Pediatric & Congenital Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Rare disease therapeutics
  • Lysosomal storage disorders
  • Orphan drug development
  • Clinical-stage biotechnology
  • Small molecule pharmaceuticals

Where Azafaros is headquartered

Location

Headquarters

HQ city
Naarden
HQ country
Netherlands
HQ region
Europe

Offices3 records

Markets served

Azafaros business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Pharmaceutical Product Sales: Pre-revenue clinical-stage biotech company. Once nizubaglustat receives regulatory approval, revenue will be generated through prescription drug sales for rare lysosomal storage disorders. The company is preparing for drug marketing authorization filings and commercial launch targeting patients with GM1/GM2 gangliosidoses and Niemann-Pick type C disease.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Azafaros product offering

Product offering

Core offering

Azafaros is a clinical-stage biotech company developing nizubaglustat (AZ-3102), an orally available, brain-penetrant azasugar small molecule with a unique dual mode of action inhibiting both NLGase and GCS enzymes. The drug is being advanced through Phase 3 registrational studies (NAVIGATE) for the treatment of rare lysosomal storage disorders including GM1 and GM2 gangliosidoses and Niemann-Pick type C disease.

Product overview

Azafaros is a clinical-stage biotech company with one lead product candidate, nizubaglustat (also referred to as AZ-3102). Nizubaglustat is an orally available, brain-penetrant small molecule azasugar with a unique dual mode of action that modulates glycosphingolipid metabolism. The company is advancing nizubaglustat through Phase 3 registrational studies (NAVIGATE) for the treatment of GM1 and GM2 gangliosidoses and Niemann-Pick type C disease. The company was founded in 2018 and holds an exclusive license from Leiden University and Amsterdam UMC to a library of novel compounds.

Differentiator

Problem solved

Functional benefit

Products and services

  • Nizubaglustat (AZ-3102) An orally available, brain-penetrant small molecule azasugar with a unique dual mode of action targeting both NLGase and GCS enzymes, being developed as a potential disease-modifying treatment for rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses and Niemann-Pick type C disease.

Quantifiable outcome

  • 22% survival increase (26 additional days) in Sandhoff disease mouse model at doses as low as 0.2 mg/kg/day
  • +3 more outcomes

Companies that use Azafaros

Customer profile

Segments1 record

Ideal customer profiles1 record

Azafaros technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Azafaros partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered research collaborator and core partnership.

  • Queen's University (Dr. Jagdeep Walia Laboratory)research collaboratorStrategic or Co-development PartnerCollaboration with Queen's University Department of Pediatrics led by Dr. Jagdeep Walia for preclinical efficacy studies of nizubaglustat in GM2 gangliosidosis (Sandhoff disease mouse model). Published in Journal of Inherited Metabolic Disease.
  • Patient Advocacy Organizationscore partnershipStrategic or Co-development PartnerCollaborations with patient organizations including National Tay-Sachs & Allied Diseases Association (NTSAD), National Niemann-Pick Disease Foundation (NNPDF), CATS Foundation, and NPUK for optimizing clinical trial design and patient engagement initiatives.

Scale indicators4 records

Recent moves7 records

Expansion highlights6 records

Azafaros competitors and assessment

Company assessment

Direct peers

  • Abeona Therapeutics: Clinical-stage biotech developing AAV gene therapies for GM1 and GM2 gangliosidoses, directly competing with Azafaros's nizubaglustat in the same lead indications using a different modality (gene therapy vs small molecule).
  • Cyclo Therapeutics: Late-stage developer of Trappsol (hydroxypropyl beta cyclodextrin) for Niemann-Pick type C disease, directly competing with nizubaglustat in the NPC indication with a different mechanism of action.

Broad incumbents

  • BioMarin Pharmaceutical: Established rare disease leader with multiple approved enzyme replacement and small molecule therapies for lysosomal storage disorders (Vimizim, Naglazyme, Aldurazyme), making it the closest large-cap comparable and likely strategic acquirer for Azafaros.
  • Ultragenyx Pharmaceutical: Commercial-stage rare disease company focused on metabolic and neurological disorders, where Azafaros's CEO Stefano Portolano previously served as Head of Europe; comparable commercial model targeting specialized rare disease treatment centers globally.
  • Sanofi (Genzyme Rare Disease): Owns the leading LSD franchise (Cerezyme, Fabrazyme, Myozyme, Aldurazyme) and miglustat (via legacy Actelion) for NPC, making it both a competitor in NPC and a likely strategic acquirer for any approved GM1/GM2 therapy.
  • Alexion / AstraZeneca Rare Disease: Large rare disease franchise (Soliris, Strensiq, Kanuma) with established commercial infrastructure in ultra-rare metabolic disorders and active BD presence in CNS and LSDs.
  • Johnson & Johnson (Janssen / Actelion): Holds miglustat (Zavesca) as the only approved NPC therapy via the Actelion acquisition; the incumbent standard of care in the NPC indication where Azafaros is running a pivotal Phase 3.
  • Takeda Pharmaceutical: Large rare disease franchise including Replagal, Elaprase, and Adynovate for LSDs; Azafaros COO previously led rare disease business development at Takeda, making it a logical strategic partner or acquirer.

Emerging players

  • IntraBio: Clinical-stage rare disease company with approved and pipeline assets in lysosomal and neurodegenerative disorders, with overlapping interest in NPC and other LSDs where nizubaglustat is being developed.
  • Passage Bio: Clinical-stage gene therapy company with CNS-targeted AAV programs including GM1 gangliosidosis, representing an alternative modality competing for the same patient population as nizubaglustat.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Azafaros social profiles

Digital presence

Azafaros compliance and trust

Trust signal

Compliance10 records

Azafaros financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Azafaros leadership team

Management profile

Number of profiles

Profiles11 records

Azafaros subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Azafaros funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Azafaros M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Azafaros

What does Azafaros do?

Azafaros is a clinical-stage biotech company developing nizubaglustat (AZ-3102), an orally available, brain-penetrant azasugar small molecule with a unique dual mode of action inhibiting both NLGase and GCS enzymes. The drug is being advanced through Phase 3 registrational studies (NAVIGATE) for the treatment of rare lysosomal storage disorders including GM1 and GM2 gangliosidoses and Niemann-Pick type C disease.

Is Azafaros a public or private company?

Azafaros is a private company. It is classified as venture growth investor backed and is currently operating.

When was Azafaros founded?

Azafaros was founded in 2018. It employs 11 to 50 people.

Where is Azafaros based?

Azafaros is headquartered in Naarden, Netherlands, in the Europe region.

How does Azafaros make money?

One revenue line is on record: pharmaceutical Product Sales.

Who are Azafaros's main competitors?

Direct peers on record are Abeona Therapeutics and Cyclo Therapeutics. Broad incumbents are BioMarin Pharmaceutical, Ultragenyx Pharmaceutical, Sanofi (Genzyme Rare Disease), Alexion / AstraZeneca Rare Disease, Johnson & Johnson (Janssen / Actelion) and Takeda Pharmaceutical. Emerging players are IntraBio and Passage Bio.

Does Azafaros have an API?

No public API is recorded for Azafaros.

What industry is Azafaros in?

Azafaros's product category is Rare Disease Pharmaceuticals. Its primary akta.pro industry code is HLAIAIAN, Rare Pediatric & Congenital Disorder Therapies. Its NAICS code is 3254 and its SIC code is 2833.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
YahooAzafaros concludes Phase III trial recruitment for GM1/GM2 gangliosidosesNetherlands-based biotechnology company Azafaros has completed patient recruitment for its Phase III clinical trial evaluating nizubaglustat for GM1/GM2 gangliosidoses, rare neurodegenerative lysosomal storage disorders. The NAVIGATE programme trial enrolled at least 75 patients across 25 clinical sites in 13 countries over an 18-month treatment period, with top-line results expected in early 2028. Recruitment is ongoing for a parallel Phase III study in Niemann-Pick type C disease, and nizubaglustat has received rare pediatric disease, orphan drug, and fast track designations from the FDA, among other regulatory designations.Clinical Trials ArenaAzafaros concludes Phase III trial recruitment for GM1/GM2 gangliosidosesAzafaros completed patient recruitment for its Phase III trial of nizubaglustat in GM1/GM2 gangliosidoses, enrolling at least 75 patients across 25 sites in 13 countries. The trial's top-line results are expected in early 2028, with recruitment ongoing in a parallel Phase III study for Niemann-Pick type C disease.BioSpaceAzafaros Completes Enrollment of Phase 3 (NAVIGATE) Study Evaluating Nizubaglustat for the Treatment of Patients with GM1/GM2 GangliosidosesAzafaros completed enrollment in its Phase 3 NAVIGATE study evaluating nizubaglustat for GM1/GM2 gangliosidoses, recruiting 75 patients across 25 sites. Enrollment in the NPC study is ongoing, with topline data expected in early 2028.AijournAzafaros to Present at BIO International Convention 2026Azafaros, a private clinical-stage biotech company based in Leiden, Netherlands, has announced it will present at the 2026 BIO International Convention in San Diego, USA, from June 22-25. The presentation will highlight progress on nizubaglustat, its lead investigational compound for rare lysosomal storage disorders with neurological involvement, which is currently in two Phase 3 registrational studies with topline data expected in 2028.Business Wire BlogAzafaros to Present at BIO International Convention 2026Azafaros announced that it will present at the BIO International Convention 2026 in San Diego, USA, from June 22-25, with its presentation scheduled for June 22 at 4:30 PM in Theater 4. The company will highlight progress on nizubaglustat, its lead investigational compound for rare lysosomal storage disorders including GM1/GM2 gangliosidoses and Niemann-Pick type C disease, which is currently in two Phase 3 registrational studies. Topline data from the NAVIGATE studies is expected in 2028, and the presentation will update stakeholders on late-stage clinical development and preparations for future regulatory interactions.BioSpaceAzafaros to Present at BIO International Convention 2026Azafaros will present at the 2026 BIO International Convention in San Diego on June 22, highlighting its lead investigational compound nizubaglustat for lysosomal storage disorders. The compound is in two Phase 3 registrational studies (NAVIGATE) for GM1/GM2 gangliosidoses and Niemann-Pick type C, with topline data expected in 2028.BioSpaceAzafaros Announces Publication of Phase 2 RAINBOW Study Data for Nizubaglustat in Molecular Genetics and Metabolism JournalAzafaros published Phase 2 RAINBOW study data on nizubaglustat for GM2 gangliosidosis and Niemann-Pick type C disease in Molecular Genetics & Metabolism. The data showed the drug reduced disease progression and seizure burden, supporting its safety and encouraging efficacy. The results support two ongoing Phase 3 registrational studies.Business Wire BlogAzafaros Announces Publication of Phase 2 RAINBOW Study Data for Nizubaglustat in Molecular Genetics and Metabolism JournalAzafaros published Phase 2 RAINBOW study data for nizubaglustat in Molecular Genetics & Metabolism, showing reduced disease progression and seizure burden in GM2 gangliosidosis and Niemann-Pick type C disease. The data supports two ongoing Phase 3 registrational studies for these conditions.Via RitzauAzafaros Strengthens Leadership Team With Appointment of Amy Sullivan as Chief Financial OfficerAzafaros announced the appointment of Amy Sullivan as Chief Financial Officer, bringing over 30 years of life sciences experience, including prior roles at IO Biotech, TABA BV, and Kiadis Pharma. Sullivan joins the company as it advances two pivotal Phase 3 studies with nizubaglustat for GM1/GM2 gangliosidoses and Niemann-Pick type C disease. The appointment is intended to support Azafaros as it prepares for drug marketing authorization filings and commercial launch.Business Wire BlogAzafaros Strengthens Leadership Team With Appointment of Amy Sullivan as Chief Financial OfficerAzafaros appointed Amy Sullivan as Chief Financial Officer, bringing over 30 years of biotech finance experience. She joins from IO Biotech, where she served as CFO. The company is advancing Phase 3 studies with nizubaglustat for GM1/GM2 gangliosidoses and Niemann-Pick type C disease.